No Data
China Resources Boya Bio-pharmaceutical Group (300294.SZ): The controlling Shareholder has cumulatively increased its Shareholding in the company by 5.8997 million shares.
On April 9, 2024, China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that it received a notice from its controlling shareholder regarding the progress of the shareholding increase plan. CHINARES PHARMA held a total of 5.8997 million shares of the company through centralized bidding trading via the Shenzhen Stock Exchange from November 8, 2024, to April 8, 2025, increasing its shareholding to 1.1700% of the company's total equity.
Earnings Miss: China Resources Boya Bio-pharmaceutical Group Co.,Ltd Missed EPS By 22% And Analysts Are Revising Their Forecasts
Liberal Arts Biotech: 2024 Annual Report Summary
Liberal Arts Biotech: 2024 Annual Report
China Resources Boya Bio-pharmaceutical Group (300294.SZ): Net income for the year 2024 is 0.397 billion yuan, a year-on-year increase of 67.18%.
On March 18, Glonghui reported that China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced its annual report for 2024, achieving revenue of 1.735 billion yuan in 2024, a year-on-year decrease of 34.58%; net income attributable to shareholders of the listed company was 0.397 billion yuan, an increase of 67.18% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.302 billion yuan, an increase of 110.77% year-on-year; EPS was 0.79 yuan. The profit distribution plan, approved by the Board of Directors during this board meeting, is: based on 504,248,738 shares, distribute 10 shares to all shareholders for every 10 shares held.
While Private Companies Own 30% of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294), Individual Investors Are Its Largest Shareholders With 37% Ownership
Some Confidence Is Lacking In China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) As Shares Slide 26%
